LiveRamp Holdings, Inc. (RAMP)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Liver Diseasesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 11/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 14.98% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- LiveRamp Shareholders Approve MMS USA Merger in Key Vote
- LiveRamp Holdings (RAMP) Could Be 7% Undervalued Following First Quarter Results
- LiveRamp (NYSE:RAMP) Posts Q2 CY2026 Sales In Line With Estimates
- LiveRamp’s (RAMP) Profits Surge Just As A Buyout Nears The Finish Line
- LiveRamp (RAMP) Tops Q1 Earnings and Revenue Estimates
- LiveRamp Adds Meta to Cross-Media Intelligence
- LiveRamp to Report Financial Results for First Quarter Fiscal 2027
- New MMA and LiveRamp Report Finds Even Small Data Gaps and Identity Errors Can Distort Marketing Measurement
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for LiveRamp Holdings, Inc..
Full RAMP Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.